GlassScriptPhysician profile
Daniel A Kaufman
NPI 1215376157
$3,597.85
in general payments reported to CMS, 2019-2025
33 companies · $382 in 2025
The $382 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $192 · 2021: $602 · 2022: $815 · 2023: $718 · 2024: $709 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,808.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $1,236.10 | 2022-2025 | Aquabeam System, Aquabeam Robotic System |
| Teleflex LLC | $378.40 | 2021-2023 | Urolift |
| Astellas Pharma US INC | $216.55 | 2019-2023 | Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $192.77 | 2019-2023 | |
| Amgen INC. | $145.01 | 2020-2023 | Xgeva |
| Laborie Medical Technologies Corp. | $117.29 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Endo Pharmaceuticals INC. | $111.77 | 2019-2021 | |
| Srs Medical Systems, INC. | $106.86 | 2021-2023 | Urocuff |
| Progenics Pharmaceuticals, INC. | $102.48 | 2022-2024 | Pylarify |
| Myovant Sciences INC. | $91.31 | 2021-2022 | |
| Pfizer INC. | $89.78 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $66.15 | 2022-2023 | Lynparza |
| Abbvie INC. | $65.61 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $59.41 | 2022-2023 | Welireg, Keytruda, Lynparza |
| Boston Scientific Corporation | $59.25 | 2022-2024 | Rezum Generator |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $47.26 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $43.50 | 2021 | |
| Coloplast Corp | $41.35 | 2021-2022 | |
| Foundation Medicine, INC. | $41.30 | 2022-2023 | |
| Telix Pharmaceuticals | $40.34 | 2024 | Illuccix |
| Ambu INC. | $38.00 | 2021 | |
| Urogen Pharma, INC. | $37.51 | 2023-2024 | Jelmyto |
| Sumitomo Pharma America, INC. | $36.79 | 2023 | Orgovyx, Gemtesa |
| Antares Pharma, INC. | $35.63 | 2022 | |
| Clarus Therapeutics INC. | $31.02 | 2021 | |
| Dendreon Pharmaceuticals LLC | $29.71 | 2022 | |
| 180 Medical, INC. | $25.20 | 2024 | |
| Rochester Medical Corporation | $22.43 | 2022 | |
| Eisai INC. | $21.59 | 2023 | |
| Halozyme INC | $18.31 | 2023 | |
| Verity Pharmaceuticals INC. | $18.06 | 2023 | Trelstar |
| Janssen Biotech, INC. | $15.60 | 2019 | |
| Cook Medical LLC | $15.51 | 2024 | Cook |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kaufman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.